Dimerix will receive an upfront payment of $30m from Amicus and up to $75m in development and regulatory milestone payments.

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) ...

These shares are having a good finish to the week. Let's find out why. The post Why Boss Energy, Capstone, Dimerix, and ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Dimerix (ASX:DXB) has filled the US gap in its network of global partnerships, today revealing a US tie-up potentially worth ...

Ainsworth Game Technology (ASX:AGI) jumped 32.4% since Thursday 24 April, finishing the week at 98 cents after announcing it ...

In one of the largest licensing deals in the Australian biotech industry, Dimerix Limited (ASX: DXB) has sealed an exclusive ...

The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.

Dimerix (ASX: DXB), an Australian drug developer, has entered into an exclusive US licensing agreement with Amicus ...

The US FDA has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III ACTION3 trial of DMX-200 for ...

DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2). The ACTION3 trial is a randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients ...